E. Krediet

Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study

Emeline L. Maillet, D. Luke, P. Hendricks, 2022, Journal of psychopharmacology.

Experiences with medical cannabis in the treatment of veterans with PTSD: Results from a focus group discussion

T. Egberts, D. G. Janssen, E. Heerdink, 2020, European Neuropsychopharmacology.

Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies

A. Niemeijer, R. Schoevers, E. Vermetten, 2020, CNS Drugs.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

R. Carhart-Harris, T. Williams, D. Goble, 2019, Psychopharmacology.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

R. Carhart-Harris, T. Williams, D. Goble, 2019, Psychopharmacology.

Reviewing the Potential of Psychedelics for the Treatment of PTSD

E. Vermetten, T. Passie, J. Breeksema, 2020, The international journal of neuropsychopharmacology.

Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?

R. Wiers, E. Salemink, E. Krediet, 2018, Journal of psychopharmacology.

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

J. Kamphuis, J. Breeksema, E. Krediet, 2024, Scientific reports.